Cephalosporin antibiotics are commonly used but can result in allergic reactions and anaphylaxis. There is no clear diagnostic approach for cephalosporin-allergic patients, and guidance for the use of other antibiotics in allergic patients is based on side chain chemical similarity and limited skin testing evidence. This project includes a clinical trial and mechanistic studies to optimize the approach to cephalosporin allergy and advance future diagnostics.

Start Date01 Aug 2024

Sponsor / Collaborator

The General Hospital Corp.

[+1]

NCT05105035 / CompletedPhase 2

A Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination With Intravenous Ceftazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients

The study investigates the effect of 14 days of twice daily doses of ARV-1801 or placebo in combination with meropenem or ceftazidime in patients hospitalized with melioidosis.

Start Date14 Jun 2022

Sponsor / Collaborator

Arrevus, Inc.Startup

NCT05074147 / Not yet recruitingPhase 3

Three Weeks Versus Six Weeks Antibiotic Therapy for Nonsurgically Treated Diabetic Foot Osteomyelitis : a Multicenter, Randomized, Open-label and Controlled Study

The aim of this clinical study is to compare the efficacy and tolerance of 3 versus 6 weeks of antibiotherapy in patients with diabetic foot osteomyelitis treated medically.

Start Date01 May 2022

Sponsor / Collaborator

Centre Hospitalier de Tourcoing

100 Clinical Results associated with Ceftazidime

100 Translational Medicine associated with Ceftazidime

100 Patents (Medical) associated with Ceftazidime

11,205

Literatures (Medical) associated with Ceftazidime

01 Dec 2024·Molecular biology reports

Detection of phylogrouping, adhesin, and extended spectrum β-lactamases genes in hospital acquired uropathogenic Escherichia coli isolates

Article

Author: El Azawy, Doaa Sh ; El-Sayed, Hend Abdalla ; Fahmy, Yasmin Ahmed ; Orabi, Eman Elshahat ; Hussein, Samia ; Attia, Osama ; El Maghraby, Hanaa M

BACKGROUND:

It has been interesting to compare the levels of antimicrobial resistance and the virulence characteristics of uropathogenic Escherichia coli (UPEC) strains of certain phylogenetic groups. The purpose of this study was to identify the frequency of phylogenetic groups, adhesin genes, antibiotic sensitivity patterns, and extended spectrum-lactamases (ESBLs) genes in hospital-acquired UPEC.

METHODS:

After UPEC isolation, the disc diffusion method was used to assess its susceptibility to antibiotics. Combination disc testing confirmed the existence of ESBL producers. Polymerase chain reaction (PCR) was used to detect genes for adhesin and ESBLs.

RESULTS:

One hundred and twenty-eight E. coli were isolated which had the highest resistance to tetracycline (96%) followed by cefoxitin (93%), cefepime (92%), ceftazidime (79%), aztreonam (77%) and sulfamethoxazole -trimethoprim (75%). About 57% of isolates were phenotypically ESBLs positive and they were confirmed by PCR. B2 phylogroup (41%) was the most frequent in E. coli isolates then group D (30%), group A (18%), and lastly group B1 (11%). ESBLs genes were more significantly prevalent in phylogroups B2 and D than other phylogroups (P < 0.001). Regarding adhesin genes, both fim H and afa were more significantly associated with group B2 than other groups (P < 0.009, < 0.032), respectively. In ESBL-positive isolates, both genes were more significantly detected compared to negative ones (P < 0.001).

CONCLUSION:

Phylogroups B2 and D of UPEC are important reservoirs of antimicrobial resistance and adhesion genes. Detection of ESBL-producing E. coli is important for appropriate treatment as well as for effective infection control in hospitals.

01 Mar 2024·Journal of global antimicrobial resistance

The occurrence of the carbapenemase gene, blaNDM-5, on a transmissible IncX3 plasmid in multidrug-resistant Escherichia coli isolated from a farm dog

Article

Author: Kassem, Issmat I ; Oueslati, Saoussen ; Osman, Marwan ; Naas, Thierry ; Daaboul, Dina ; Dabboussi, Fouad ; El Omari, Khaled

OBJECTIVES:

In-depth phenotypic and genomic analyses on a carbapenem-resistant Escherichia coli isolate, recovered from the faeces of a farm dog in Lebanon, focusing on its antimicrobial resistance (AMR) patterns and the underlying resistome.

METHODS:

E. coli strain EC-106 was identified using MALDI-TOF-MS. Analyses using Carba NP, immunochromatographic assay NG Carba5, and other antimicrobial susceptibility testing were performed. Whole-genome sequencing (WGS) using the Illumina technology and different software available at the Center of Genomic Epidemiology wwere used to predict the resistome, sequence type (ST), plasmid types, and virulence genes.

RESULTS:

Susceptibility testing revealed that E. coli EC-106 was multi-drug resistant, including against newer antimicrobials such as imipenem-relebactam (MIC = 16 µg/mL), meropenem-vaborbactam (MIC = 16 µg/mL), and ceftazidime-avibactam (MIC > 32 µg/mL), but remained susceptible to aztreonam (MIC = 0.12 µg/mL), aztreonam-avibactam (MIC = 0.06 µg/mL), and cefiderocol (MIC = 0.5 µg/mL). WGS analyses showed that E. coli EC-106 carried 13 acquired resistance genes associated with resistance to β-lactams (bla_NDM-5 and bla_TEM-1B), aminoglycosides (aac(3)-IId, aph(3')-Ia, aadA1, and aadA2), tetracyclines (tetA), amphenicols (partial catA1), macrolides (mphA), sulphonamides (sul1 and sul3), trimethoprim (dfrA12), and quaternary ammonium compounds (partial qacE). The bla_NDM-5 was located on an IncX3 plasmid. The isolate was predicted to be a human pathogen (92.9%) and belonged to ST1011.

CONCLUSION:

To our knowledge, this is the first report of the detection of an IncX3 plasmid carrying the bla_NDM-5 gene in animals in Lebanon, highlighting the severe AMR challenges in the country. Taken together, our current and previous findings suggest that bla_NDM-5 might be spreading in different hosts and genetic backgrounds across clinical and non-clinical settings.

News (Medical) associated with Ceftazidime

06 Jun 2024

·www.biospace.com

MicuRx: Successful Completion of Phase I Clinical Trial for Self-Developed MRX-8 Antibacterial Drug in China

According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative. Bacteria ("MDR-GNB"), indicating significant clinical application potential. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3% during this period. SHANGHAI, June 6, 2024 /PRNewswire/ -- Recently, Shanghai MicuRx Pharmaceutical Co., Ltd. ("MicuRx", 688373.SH) successfully completed the Phase I clinical trial of its self-developed new injectable polymyxin antibacterial drug MRX-8 in China, achieving the expected goals. MRX-8 is primarily used to treat infections caused by multidrug-resistant Gram-negative bacteria. This significant milestone marks a crucial step towards MRX-8 becoming a safe and effective new antibacterial drug. China Phase I Clinical Trial Results The Phase I clinical trial in China was a randomized, double-blind, placebo-controlled study designed to evaluate the safety, tolerability, and pharmacokinetic characteristics of MRX-8 in healthy Chinese subjects. The trial included single ascending dose and multiple ascending dose components, demonstrating that MRX-8's drug exposure in the human body increases proportionally with the dose. The study demonstrated that at the expected clinical dose of 2.5 mg/kg once daily, MRX-8 can achieve ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria. Moreover, MRX-8 exhibited good safety in healthy Chinese adults. Throughout the study, no subjects withdrew or terminated the trial due to adverse events, and no CTCAE Grade 3 or higher adverse events occurred. The most common adverse events were mild sensory reduction and decreased glomerular filtration rate, all of which were CTCAE Grade 1 and resolved without intervention. Only two subjects in the multiple dose group experienced CTCAE Grade 2 adverse events, both of which were injection site reactions.. The Study's Impact and Future Plans As one of the company's important new drug development product pipelines, the successful completion of the Phase I clinical trial of MRX-8 in China is of great significance. The study results indicate that MRX-8 exhibits good safety in healthy Chinese adults at the expected clinical dose, laying a solid foundation for its future clinical use. The success of this clinical trial not only provides strong data support for subsequent clinical development, but also enhances confidence in its future application in treating multidrug-resistant Gram-negative bacterial infections. This marks a crucial step forward for MRX-8 in becoming a safe and effective new antibacterial drug. The company will combine the results and data from both the US and China Phase I clinical trials to formulate the next steps in MRX-8's clinical development plan. The company will actively explore development pathways for different potential indications, aiming to make MRX-8 a new antibacterial drug with significant clinical value for treating multidrug-resistant Gram-negative bacterial infections, in order to meet the rapidly growing need for clinical treatment. The company is committed to creating maximum value for society and the company, driving MRX-8 towards market availability, and providing new hope for patients. About MRX-8 MRX-8 is a novel injectable polymyxin antibacterial drug independently developed by MicuRx Pharmaceuticals, primarily used to treat severe infections caused by multidrug-resistant Gram-negative bacteria. Traditional polymyxin drugs have limited clinical use due to their high risk of nephrotoxicity and neurotoxicity. MRX-8, through meticulous structural design, not only maintains or improves therapeutic efficacy, but also significantly reduces these toxic risks. Results from the Phase I clinical trial completed in the United States in 2022 showed that MRX-8 achieves ideal therapeutic effects against infections caused by multidrug-resistant Gram-negative bacteria such as Escherichia coli, Pseudomonas aeruginosa, and Acinetobacter baumannii. Multidrug-Resistant Gram-Negative Bacteria and Market Demand Gram-negative bacteria are resistant to multiple drugs and are increasingly resistant to most available antibiotics. Multidrug-resistant Gram-negative bacteria (MDR-GNB) are a specific class of Gram-negative bacteria whose multidrug resistance is defined as resistance to three or more commonly prescribed antibiotics (ceftazidime, ciprofloxacin, meropenem, gentamicin, ampicillin/sulbactam, or piperacillin/tazobactam). Infections caused by MDR-GNB have a mortality rate five times higher than infections caused by conventional Gram-negative bacteria. Globally, infections caused by multidrug-resistant Gram-negative bacteria have become a major public health challenge. According to the World Health Organization (WHO), millions of patients face treatment difficulties or even life-threatening conditions due to resistant bacterial infections each year. In hospitals and intensive care units, infections caused by resistant Gram-negative bacteria result in high mortality rates and significant treatment costs, posing substantial pressure on healthcare systems. In China, the total number of days of antibiotic treatment for MDR-GNB infections increased from 43 million days in 2018 to 68.4 million days in 2023, with a compound annual growth rate of 10.3%.[1] Currently, the market has limited options for effectively treating multidrug-resistant Gram-negative bacterial infections, and the severe side effects of traditional polymyxin drugs further restrict their clinical use. The development and clinical trial results of MRX-8 address this unmet market need. MRX-8 not only shows excellent safety and tolerability but also demonstrates strong antibacterial activity against multidrug-resistant Gram-negative bacteria, indicating significant clinical application potential. [1] Data source: Frost & Sullivan Analysis View original content: SOURCE MicuRx Pharmaceuticals

Phase 1Clinical ResultMicrobial therapy

25 Apr 2024

·www.biospace.com

FDA Approves UTILITY’s New Antibiotic for Uncomplicated UTI in Women

Pictured: FDA signage at its office in Washington, DC/iStock, JHVEPhoto The FDA on Wednesday approved the use of UTILITY therapeutics’ oral antibiotic pivmecillinam, which will now carry the brand name Pivya, for the treatment of adult women with uncomplicated urinary tract infections. In its approval announcement, the FDA noted that uncomplicated urinary tract infections (UTIs) are bacterial infections of the bladder in females with no structural abnormalities of their urinary tract. The regulator added that approximately one-half of all women experience at least one UTI in their lifetime. Pivya is indicated for patients whose UTIs are caused by susceptible strains of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus. UTILITY is working to make Pivya available in the U.S. in 2025, according to reporting from The New York Times. The antibiotic’s approval “will provide an additional treatment option for uncomplicated UTIs,” Peter Kim, director of the Division of Anti-Infectives at the FDA’s Center for Drugs Evaluation and Research, said in a statement. “Uncomplicated UTIs are a very common condition … and one of the most frequent reasons for antibiotic use.” The FDA’s approval on Wednesday was supported by data from three clinical trials, which compared Pivya to placebo, another oral antibacterial agent as well as to the anti-inflammatory drug ibuprofen. All three studies primarily evaluated Pivya’s composite response rate, which included clinical cure and microbiological response. In the placebo study, Pivya treatment elicited a 62% composite response rate at eight to 14 days after enrollment. Only 10% of placebo counterparts achieved the composite response endpoint. When compared with another antibacterial agent, Pivya elicited a 72% composite response rate versus 76% in those who received the other drug. In the third trial, 66% of patients treated with Pivya achieved composite response compared to only 22% of those who were given ibuprofen. In terms of safety, Pivya was overall well-tolerated and its most common side effects were nausea and diarrheas. The antibiotic carries warnings for hypersensitivity reactions, carnitine depletion, Clostridioides difficile-associated diarrhea and severe cutaneous adverse reactions. It should not be taken by patients with known histories of severe hypersensitivities against beta-lactam drugs. Pivya can also interfere with a newborn screening test for the rare metabolic disorder isovaleric acidemia. Pivya’s active ingredient pivmecillinam is an aminopenicillin, which is a specific subclass of beta-lactams that work by disrupting the synthesis of the bacterial cell wall. According to UTILITY’s website, pivmecillinam has already been commercially approved for more than 40 years outside the U.S. and has long been used to successfully treat UTIs. Pivmecillinam has also been recommended as the frontline treatment option in many countries. Tristan Manalac is an independent science writer based in Metro Manila, Philippines. Reach out to him on LinkedIn or email him at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

Clinical ResultDrug ApprovalPhase 3

09 Apr 2024

·www.biospace.com

Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics

Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it has been awarded a grant from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The grant award is to support initial preclinical activities on the antibiotics program recently acquired from Spexis. The initial funding of up to USD 0.9 million will support the work until candidate nomination in the second half of 2024. Basilea could receive additional funding from CARB-X, to continue preclinical and early clinical development of the antibiotics program, if the project achieves certain milestones. Dr. Laurenz Kellenberger, Chief Scientific Officer of Basilea, said: "We are delighted by CARB-X’s commitment to fund the development of these promising, first-in-class antibiotics, which have the potential to address an unmet medical need in the hospital-based treatment of severe infections, caused by Gram-negative bacteria. We look forward to working with CARB-X to bring our new antibiotics to patients." The program comprises antibiotics targeting LptA, which is part of the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria. The molecules belong to one of the very few novel classes of antibiotics in development. Potent and rapid bactericidal activity has been shown in vitro and in vivo against Gram-negative bacteria of the Enterobacteriaceae family, such as E. coli and K. pneumoniae, including strains resistant to beta-lactams and colistin, an antibiotic regarded as last-resort therapy.1 Enterobacteriaceae have been highlighted by the World Health Organization as priority pathogens, against which new antibiotics are urgently needed.2 CARB-X’s funding for this project is provided in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response; Biomedical Advanced Research and Development Authority; Antibacterials branch; under agreement number 75A50122C00028; and by awards from Wellcome (WT224842) and Germany’s Federal Ministry of Education and Research (BMBF). The content of this press release is solely the responsibility of the authors and does not necessarily represent the official views of CARB-X or any of its funders. About CARB-X CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator) is a global non-profit partnership dedicated to supporting early-stage antibacterial research and development to address the rising threat of drug-resistant bacteria. CARB-X supports innovative therapeutics, preventatives and rapid diagnostics. CARB-X is led by Boston University and funded by a consortium of governments and foundations. CARB-X funds only projects that target drug-resistant bacteria highlighted on the CDC’s Antibiotic Resistant Threats list, or the Priority Bacterial Pathogens list published by the WHO, with a priority on those pathogens deemed Serious or Urgent on the CDC list or Critical or High on the WHO list. | X (formerly Twitter) @CARB_X About Basilea Basilea is a commercial-stage biopharmaceutical company founded in 2000 and headquartered in Switzerland. We are committed to discovering, developing and commercializing innovative drugs to meet the needs of patients with severe bacterial and fungal infections. We have successfully launched two hospital brands, Cresemba for the treatment of invasive fungal infections and Zevtera for the treatment of bacterial infections. In addition, we have preclinical and clinical anti-infective assets in our portfolio. Basilea is listed on the SIX Swiss Exchange (SIX: BSLN). Please visit basilea.com. Disclaimer This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For further information, please contact: Peer Nils Schröder, PhD Head of Corporate Communications & Investor Relations Basilea Pharmaceutica International Ltd, Allschwil Hegenheimermattweg 167b 4123 Allschwil Switzerland Phone +41 61 606 1102 E-mail media_relations@basilea.com investor_relations@basilea.com This press release can be downloaded from . References M. Schuster, E. Brabet, K. K. Oi et al. Peptidomimetic antibiotics disrupt the lipopolysaccharide transport bridge of drug-resistant Enterobacteriaceae. Science Advances 2023 (9), eadg3683 (Accessed: April 08, 2024) Press release (PDF)

Qualified Infectious Disease Product

100 Deals associated with Ceftazidime

External Link

KEGG	Wiki	ATC	Drug Bank
D07654	Ceftazidime	J01DD02	DB00438

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Bacterial Infections	CN	Northeast Pharmaceutical Group Co., Ltd.	01 Jan 1993
Bone and joint infections	US	PAI Holdings LLC	19 Jul 1985
Central Nervous System Infections	US	PAI Holdings LLC	19 Jul 1985
Gynecological infection	US	PAI Holdings LLC	19 Jul 1985
Intraabdominal Infections	US	PAI Holdings LLC	19 Jul 1985
Lower Respiratory Tract Infections	US	PAI Holdings LLC	19 Jul 1985
Sepsis	US	PAI Holdings LLC	19 Jul 1985
Skin and skin structure infections	US	PAI Holdings LLC	19 Jul 1985
Urinary Tract Infections	US	PAI Holdings LLC	19 Jul 1985
Gram-Negative Bacterial Infections	-	VJGJ, Inc.	01 Jan 1983
Gram-Positive Bacterial Infections	-	VJGJ, Inc.	01 Jan 1983

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hospital-acquired pneumonia	Phase 3	CN	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	JP	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	AR	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	BR	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	BG	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	CL	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	CZ	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	FR	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	HU	GlaxoSmithKline Manufacturing SpA	07 May 2014
Hospital-acquired pneumonia	Phase 3	IN	GlaxoSmithKline Manufacturing SpA	07 May 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03978091 (Pubmed) Manual	Phase 1	-	19	Aztreonam+Ceftazidime+Avibactam	fvxajnpopu(cfkheqwepi) = jhzoobrott gvuxdpxjcf (fpnqsnqadp ) View more	Positive	17 Nov 2022
NCT02927847 (CTgov)	Phase 1/2	Smoking	35	Nicotine Patch (BA (Behavioral Activation) + VLNC (Very Low Nicotine Cigarettes))	zicptkfesa(jpnfvndkao) = nrezuecgow fbgodbwxhj (ajzvjftsgt, ehznazzsfl - tgdunakvvp) View more	-	28 Jun 2022
				Nicotine Patch (VLNC (Very Low Nicotine Cigarettes) Only)	zicptkfesa(jpnfvndkao) = pqqsgscfws fbgodbwxhj (ajzvjftsgt, nfmgrkrmlg - ijtzdjmtao) View more
NCT02787057 (CTgov)	Not Applicable	Peritoneal dialysis-associated peritonitis	80	ceftazidime+vancomycin (Control Group)	rdxfgrcobq(ssbtbyeqfn) = eajuhmctza yshujhppgy (crupcvmoni, pvwcsxjwuv - ybgfaxluop) View more	-	26 Mar 2020
				moxifloxacin+vancomycin (Study Group)	rdxfgrcobq(ssbtbyeqfn) = jrsjhftial yshujhppgy (crupcvmoni, hmxzkqytkk - detcxydsfc) View more
NCT02538042 (VLNCCue, CTgov)	Not Applicable	Cigarette Smoking	87	MCE++Nicotine patch+SPECTRUM Nicotine Research Cigarettes (0.07 mg) (MCE+)	fmnpbodquw(boknshaddv) = wjghttjmiq fkvapstqcs (xssspbkwte, bifukbmrid - cambpywurw) View more	-	14 Nov 2018
				MCE-+Nicotine patch+SPECTRUM Nicotine Research Cigarettes (0.07 mg) (MCE- (Control))	fmnpbodquw(boknshaddv) = jlhiaapprm fkvapstqcs (xssspbkwte, rsfoaktbba - pnmvjildot) View more
ARVO2016	Not Applicable	Endophthalmitis First line	588	Amikacin	disubazghl(mthqneicpp) = may be a concern eiikzdifne (yjsskcnbcn )	Positive	01 May 2016
Pubmed \| Perit Dial Int	Not Applicable	Peritonitis	10	Ceftazidime	hfbyuceipo(kkadwvvbxx) = ffhbodwagm swqowgxgbm (kwfdivoiwr )	Positive	01 Nov 2003
Pubmed \| Am J Kidney Dis	Not Applicable	First line	10	ceftazidime	eyupunuuor(hyiwfnqyvv) = kfvhxytpyi uizbnypgjp (hnbwcuocrl, 14) View more	-	01 Jan 1999
				ceftazidime	eyupunuuor(hyiwfnqyvv) = qezzowadyl uizbnypgjp (hnbwcuocrl, 14) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis